scholarly journals POS1144 SERUM URIC ACID TO CREATININE RATIO IS ASSOCIATED WITH URINARY URIC ACID EXCRETION IN PATIENTS WITH GOUT

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 851.2-851
Author(s):  
Z. Zhong ◽  
Y. Huang ◽  
X. Huang ◽  
Q. Huang ◽  
Y. Liu ◽  
...  

Background:Underexcretion of uric acid is the dominant mechanism leading to hyperuricemia [1] and the 24-hour urinary uric acid excretion is an important measurement. However, it is inconvenient due to accurate timing and complete collection of the specimen.Objectives:The aim of this study was to investigate the relationship between serum uric acid to creatinine ratio (sUACR) and 24-hour urinary uric acid excretion in gout patients.Methods:A total of 110 gout patients fulfilling 2015 ACR/EULAR classification criteria from Guangdong Second Provincial General Hospital from January 2019 to January 2021 were retrospectively enrolled in this study. Patients were divided into underexcretion group (<3600 μmol/24h) and non-underexcretion group (≥3600 μmol/24h). The correlation between sUACR and 24-hour urinary uric acid excretion was analyzed by the Pearson’s correlations analysis. Receiver operation characteristic (ROC) curves were performed to assess the utility of sUACR for discriminating between underexcretion group and non-underexcretion group. Furthermore, the risk factors of uric acid underexcretion were evaluated using binary logistic regression analysis.Results:sUACR in the underexcretion group was significantly lower than the non-underexcretion group (p=0.0001). Besides, sUACR was positively correlated with 24-hour urinary uric acid excretion (r=0.4833, p<0.0001). Furthermore, ROC suggested that the area under the curve (AUC) of sUACR was 0.728, which was higher that of serum uric acid and creatinine. The optimal cutoff point of sUACR was 5.2312, with a sensitivity and specificity of 71.9% and 67.9%. Logistic analysis results revealed that decreased sUACR (<5.2312) was an independent risk factor of underexcretion of uric acid (OR =5.510, 95% CI: 1.952-15.550, P=0.001).Conclusion:sUACR is lower in gout patients with underexcretion of uric acid and may serve as a useful and convenient marker of assessing underexcretion of uric acid in gout patients.References:[1]Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47: 610–13.Figure 1.A. Comparison of serum uric acid to creatinine ratio between underexcretion group and non-underexcretion group. B. Correlation between serum uric acid to creatinine ratio and 24h uric acid excretion.Disclosure of Interests:None declared.

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 474-474
Author(s):  
Yoshiki Shimizu ◽  
Tsuyoshi Sakurada ◽  
Sayuri Matsuoka ◽  
Kei Yui ◽  
Takayuki Hosoi

Abstract Objectives This study was aimed to evaluate the effect of vine tea extract (VE) which contained ampelopsin (AMP) on postprandial serum uric acid levels. Methods A randomized, placebo controlled, and crossover study was performed from January 2018 to June 2018. The participants were Japanese male whose fasting serum uric acid levels were between 5.0 mg/dL and 7.0 mg/dL. The purine (RNA) loading test was conducted in this study. In brief, after fasting blood collection, the subjects ingested 4 g of yeast RNA and trial supplements (500 mg of VE (150 mg of AMP) or placebo), their blood and urine were subsequently collected every 1 hr for 4 hr. Uric acid and creatinine (Cr) levels in the blood and urine were measured. The primary outcome was postprandial uric acid area under the curve (AUC) and the secondary outcomes were postprandial uric acid, Cr clearance, urinary uric acid excretion, uric acid clearance, and fractional excretion of uric acid (FEUA). To investigate the urate lowering mechanism of VE, effect of VE or AMP on xanthine oxidase (XO) and urate transporter function was assessed in vitro. Results Of 119 participants screened, 36 males who met inclusion criteria were enrolled and the subjects were randomly assigned to two groups. Of these, 16 in X group and 18 in Y group were completed of the study. The values were expressed as mean ± SE. The postprandial uric acid AUC of VE (199.14 ± 62.38 mg · min/dL) was lower than that of placebo (214.41 ± 66.91 mg · min/dL), but it was not significant (P = 0.166). On the other hand, intake of VE induced the increase of urinary uric acid excretion (180 min; VE 0.58 ± 0.03 mg/kg/hr; P0.52 ± 0.03 mg/kg/hr; P = 0.044) and FEUA (180 min; VE 0.58 ± 0.03 mg/kg/hr; P 0.52 ± 0.03 mg/kg/hr; P = 0.044). These results suggest VE facilitate the uric acid excretion. An exploratory efficacy analysis was performed on 23 subjects whose eGFR values were less than 89 mL/min. As a result, the intake of VE suppressed postprandial uric acid elevation in those subjects significantly. AMP and VE inhibited the activity of XO in vitro. In addition, AMP weakly inhibited the function of OAT4, one of the urate reabsorption transporters. Conclusions These results suggested that intake of VE inhibited uric acid synthesis and facilitated of urate excretion, thereby suppression of the elevation of postprandial serum uric acid was observed. Funding Sources This study was supported by FANCL Corporation.


Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2562
Author(s):  
Oshima ◽  
Shiiya ◽  
Nakamura

The authors previously confirmed the serum uric acid-lowering effects of the combination of glycine and tryptophan in subjects with mild hyperuricemia. This study examined whether combined supplementation with glycine and tryptophan suppressed the elevation in serum uric acid levels caused by purine ingestion and accelerated urinary uric acid excretion in subjects with lower urate excretion using a randomized, single-blind, placebo-controlled, crossover clinical trial design. Healthy Japanese adult males with lower urate excretion ingested water containing purines in addition to dextrin (placebo), tryptophan, glycine, or a glycine and tryptophan mixture. The combined supplementation with glycine and tryptophan significantly reduced the elevated serum uric acid levels after purine ingestion. Glycine alone and in combination with tryptophan significantly increased urinary uric acid excretion and urate clearance compared with the effects of the placebo. Urinary pH increased by the ingestion of the mixture. These results suggested that the improved water solubility of uric acid due to increased urinary pH contributed to the increase of urinary uric acid excretion.


2018 ◽  
Author(s):  
Xuedong Ding ◽  
Manman Li ◽  
Shoufa Qian ◽  
Yuying Ma ◽  
Tianyi Fang ◽  
...  

AbstractBreast cancer resistance protein (BCRP) and multidrug resistance protein 4 (MRP4) are involved in uric acid excretion in humans and mice. Despite evidence suggesting that chicken renal proximal tubular epithelial cells participate in uric acid secretion, the roles of BCRP and MRP4 in chickens remain unclear. This study evaluated the relationship between chicken BCRP and MRP4 expression and renal function in the liver, kidneys, and intestines. Sixty 20-day-old Isa brown laying hens were randomly divided into four groups: a control group (NC) and groups provided with sulfonamide-treated drinking water (SD), a diet supplemented with fishmeal (FM), and an intraperitoneal injection of uric acid (IU). Serum uric acid, creatinine, and blood urea nitrogen (BUN) levels were significantly higher in the SD and IU groups than in the NC group. BCRP and MRP4 levels in the SD and IU groups were significantly increased in the kidneys and ileum and decreased in the liver. In the FM group, BCRP and MRP4 were significantly increased in the kidneys and slightly increased in the ileum. These results demonstrate that chicken BCRP and MRP4 are involved in renal and intestinal uric acid excretion. When renal function is impaired, serum uric acid increased and BCRP and MRP4 in the liver, kidneys, and ileum exhibit compensatory increases; when renal function is normal, serum uric acid changes have no effect on ileum BCRP and MRP4 expression. Therefore, this study may provide the references to the uric acid regulation in human.


2019 ◽  
Vol 47 (05) ◽  
pp. 1133-1147
Author(s):  
Yalin Zhang ◽  
Han Su ◽  
Juan Zhang ◽  
Juan Kong

Hyperuricemia is a metabolic disease of the kidney that results in decreased uric acid excretion. Here, we aimed to investigate the effects of ginsenosides and anserine on hyperuricemia and the expression of aquaporin (AQP) 1–4, which are indicators of renal excretion. Ginsenosides and anserine were administered separately or together after the establishment of hyperuricemia with adenine in BALB/c mice. Renal function indexes such as serum uric acid, creatinine, and urea nitrogen were measured in each group of mice, and the expression of AQP1–4 in renal tissues was detected. Serum uric acid and urea nitrogen were decreased in the ginsenoside and the anserine +UA groups. Meanwhile, the uric acid excretion and clearance rate were clearly increased in the co-treatment +UA group ([Formula: see text].05). Moreover, ginsenosides or anserine ginsenosides or anserine alone and treatment with both increased the expression of AQP1–4; however, the synergistic effects were more significantly enhanced ([Formula: see text].01). We provide the first reported evidence that ginsenosides and anserine have synergistic effects on uric acid excretion. The improvement in renal function in hyperuricemic mice after treatment with ginsenosides and anserine may result from up-regulation of AQP1–4 expressions.


2015 ◽  
Vol 21 (7) ◽  
pp. 346-348 ◽  
Author(s):  
Worawit Louthrenoo ◽  
Sith Hongsongkiat ◽  
Nuntana Kasitanon ◽  
Suparaporn Wangkaew ◽  
Kanon Jatuworapruk

2019 ◽  
Vol 24 (S1) ◽  
pp. 92-102
Author(s):  
Daisuke Okui ◽  
Tomomitsu Sasaki ◽  
Masahiko Fushimi ◽  
Tetsuo Ohashi

Abstract Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), increases urinary uric acid excretion. The aim of this study is to examine the pharmacokinetics, pharmacodynamics, and safety of dotinurad according to the type of hyperuricemia, with or without concomitant use of xanthine oxidase inhibitor, in uric acid “overproduction type” patients. Methods This open-label clinical pharmacology study was conducted in a hospital. Dotinurad 1 mg was administered for 7 days to hyperuricemic patients with uric acid “overproduction type” (overproduction group, n = 6; and combination group, n = 6) and uric acid “underexcretion type” (underexcretion group, n = 6). In the combination group, topiroxostat 80 mg was used concomitantly. Results No significant differences were observed in pharmacokinetics and safety between overproduction group and underexcretion group, and the percent change in serum uric acid level and the amount of urinary uric acid excretion after administration were comparable. In “overproduction type” patients of combination group, the percent change in serum uric acid level significantly increased and the amount of urinary uric acid excretion significantly decreased compared to those of overproduction group. No clinically meaningful differences were observed in safety between the overproduction group and the combination group. Conclusion In inpatients, differences in hyperuricemic type did not significantly influence the pharmacokinetics, pharmacodynamics, and safety of dotinurad. Moreover, in “overproduction type”, the coadministration of dotinurad and topiroxostat had an add-on serum uric acid lowering effect and suppressed urinary uric acid excretion. Trial registration ClinicalTrials.gov Identifier: NCT02837198.


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Jing Pan ◽  
Liang Ma ◽  
Ping Fu

Abstract Background and Aims The barks of Liriodendron Chinense (Hemsl.) Sarg is used in folk for expelling “wind and dampness”, alleviating rheumatic arthralgia in traditional Chinese medicine. The aim of the study was to evaluate the protective effect of ethanol extract of the barks of Liriodendron Chinense (Hemsl.) Sarg (EELC) in a mouse model of hyperuricemic nephropathy (HN) and the mechanisms involved. Method EELC at a respective dose of 250 mg/kg/d or 500 mg/kg/d were orally administered to HN mice induced by a mixture of adenine (160 mg/kg/d)/potassium oxonate (2.4 g/kg/d) for 21 days. At the end of the treatment, serum uric acid, kidney functions (serum creatinine, BUN and urine microalbumin), 24-h urine uric acid excretion, as well as kidney pathological changes were investigated by biochemical assay, histopathological score, immunofluorescence and histochemistry, RT-PCR, and western blotting analysis. Results Oral administration of EELC to HN mice lowered serum uric acid, improved renal functions and attenuated renal fibrosis, especially the high-dose of EELC. EELC treatment also inhibited the activation of NF-κB, ASK1/JNK/c-Jun, JAK2/STAT3 signaling pathways and reduced the release of pro-inflammatory cytokine TNF-α in the kidneys of HN mice. Furthermore, EELC remarkably increased urine uric acid excretion of HN mice, which may be achieved by the upregulation of organic anion transporter 1 (OAT1), OAT3 and ATP-binding cassette subfamily G member 2 (ABCG2) proteins. Conclusion EELC alleviated the progression of HN by suppressing the activation of NF-κB, ASK1/JNK/c-Jun and JAK2/STAT3 signaling pathway, reducing the infiltration of inflammatory factors and uric acid accumulation in the kidney. Figure Date are represented as the mean ± SD. *p&lt;0.05,**p&lt;0.01,***p&lt;0.001, ****p&lt;0.0001 vs. control, §p &lt;0.05, §§p&lt;0.01, §§§p&lt;0.001,§§§§p&lt;0.0001 vs. model.


Sign in / Sign up

Export Citation Format

Share Document